SCHEMBL2598442

SCHEMBL2598442

CC1(C)OC(=O)[C@@H]([C@H](C=O)OCc2ccccc2)O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 2/20 0.35
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
GLA P06280 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MAOB P27338 1/20 0.32
SIRT1 Q96EB6 3/20 0.31
ELANE P08246 1/20 0.31
CTSG P08311 1/20 0.31
PRTN3 P24158 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2598446 1.00 SLC1A3 (0.37) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2598522 0.80 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2598530 0.80 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2598554 0.79 IDO1 (0.37) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2598551 0.79 IDO1 (0.37) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2598549 0.78 SLC1A3 (0.38) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL14884567 0.74 TMEM97 (0.38) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL8743570 0.74 TMEM97 (0.38) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL14884574 0.74 TMEM97 (0.38) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL14884516 0.74 TMEM97 (0.38) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
EP-2571864-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS Array Biopharma, Inc. (US) 2013-03-27 EP disclosed
WO-2011146335-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 SLC1A3 760/4885SLC1A2 558/4885SLC1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.